Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Codexis, Inc.    CDXS

CODEXIS, INC.

(CDXS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (USD)
Sales 2020 68,5 M - -
Net income 2020 -23,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -30,0x
Yield 2020 -
Sales 2021 81,8 M - -
Net income 2021 -19,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -36,3x
Yield 2021 -
Capitalization 698 M 698 M -
Capi. / Sales 2020 10,2x
Capi. / Sales 2021 8,54x
Nbr of Employees 161
Free-Float 96,7%
More Financials
Company
Codexis, Inc. is a protein engineering company. The Company is engaged in the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. The Company operates through its two segments, such as the performance enzymes and novel biotherapeutics. It provides enzyme optimization services from small scale through to commercial quantities and also develops biocatalyst products. It is... 
More about the company
Notations Surperformance© of Codexis, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about CODEXIS, INC.
09/08CODEXIS : to Present at Two Virtual Investment Conferences in September
AQ
09/08Codexis to Present at Two Virtual Investment Conferences in September
GL
08/10CODEXIS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
08/07CODEXIS : 2Q Earnings Snapshot
AQ
08/06CODEXIS, INC. : Results of Operations and Financial Condition, Change in Directo..
AQ
08/06Codexis Reports Second Quarter 2020 Financial Results
GL
08/06Codexis Adds Dr. Jennifer L. Aaker to its Board of Directors
GL
07/30Codexis to Hold Second Quarter 2020 Conference Call on August 6
GL
06/23Codexis and Molecular Assemblies Partner to Transform the Field of DNA Synthe..
GL
06/22CODEXIS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/16Codexis Announces the Election of New Directors at its Annual Meeting of Stoc..
GL
06/01Codexis and Alphazyme Partner to Offer Novel Enzymes to Life Science and Diag..
GL
05/27Codexis to Participate in Two Virtual Investment Conferences
GL
05/11Codexis to Present at the UBS Virtual Healthcare Conference
GL
05/08CODEXIS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
More news
News in other languages on CODEXIS, INC.

- No features available -

More news
Chart CODEXIS, INC.
Duration : Period :
Codexis, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CODEXIS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 18,83 $
Last Close Price 11,81 $
Spread / Highest target 94,8%
Spread / Average Target 59,5%
Spread / Lowest Target 27,0%
EPS Revisions
Managers
NameTitle
John J. Nicols President, Chief Executive Officer & Director
Bernard J. Kelley Chairman
Karl A. Schoene Senior Vice President-Development & Operations
Ross Taylor Senior VP, Chief Financial & Accounting Officer
Hicham Alaoui VP-Bio Therapeutics Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CODEXIS, INC.-26.14%698
LONZA GROUP AG61.04%45 471
SEATTLE GENETICS, INC.61.87%32 181
CELLTRION, INC.42.82%29 371
IQVIA HOLDINGS INC.-2.08%28 939
MODERNA, INC.255.16%27 412